News & events

News & events

Filter by:
  • Management TeamNews

VarmX recognised with two prestigious industry award nominations

Nominated for the 2026 Prix Galien USA “Best Startup” Award, and shortlisted with partner CSL for “Deal of the Year”...

  • News

VarmX enrols first participant in global Phase 3 EquilibriX-S trial evaluating VMX-C001 in urgent surgery

First participant enrolled: EquilibriX-S (NCT07288489), a landmark registrational Phase 3 study of VMX-C001 vs usual pharmacologic care in patients taking...

  • Scientific publications

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

The absence of an adequate reversal strategy to prevent and stop potential life-threatening bleeding complications is a major drawback to...

  • News

VarmX raises seed capital for development of VMX-C001

VarmX, a Dutch, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis,...

VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs

Portfolio